Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Current and future immunotherapy targets in autoimmune neurology.
Multiple sclerosis: A lifestyle disease?
Effectiveness and cost-effectiveness of interferon beta and glatiramer acetate in the UK Multiple Sclerosis Risk Sharing Scheme at 6 years: a clinical cohort study with natural history comparator.
Regenerative cellular therapies for neurologic diseases.
Erratum to: Antibody-mediated neutralization of myelin-associated EphrinB3 accelerates CNS remyelination.
Myelin Gordon Research Conference
A Unified Frequency Domain Model to Study the Effect of Demyelination on Axonal Conduction.
Infectious mononucleosis at the United States Military Academy. A prospective study of a single class over four years.
Optical coherence tomography and neurodegeneration: are eyes the windows to the brain?
Tolerability and Pulmonary Pharmacodynamic Effects During Treatment Initiation of Once-Daily Oral Fingolimod in Subjects With Moderate Asthma.
Myelin-specific Th17 cells induce severe relapsing optic neuritis with irreversible loss of retinal ganglion cells in C57BL/6 mice.
Channelopathy-related SCN10A gene variants predict cerebellar dysfunction in multiple sclerosis.
Epigenetic modifications of Dexras 1 along the nNOS pathway in an animal model of multiple sclerosis.
Individualized quality of life of severely affected multiple sclerosis patients: practicability and value in comparison with standard inventories.
Comparative effectiveness of early Natalizumab treatment in JC virus-negative relapsing-remitting multiple sclerosis.
Leflunomide: mode of action in the treatment of rheumatoid arthritis.
Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs.
Product Portfolio, Meda
Glycoproteins as targets of autoantibodies in CNS inflammation: MOG and more.
Glatiramer acetate in combination with minocycline in patients with relapsing--remitting multiple sclerosis: results of a Canadian, multicenter, double-blind, placebo-controlled trial.
Remote Physical Activity Monitoring in Neurological Disease: A Systematic Review.
The cytoskeleton as a novel therapeutic target for old neurodegenerative disorders.
Tumor necrosis factor-α impairs oligodendroglial differentiation through a mitochondria-dependent process.
Cost-effectiveness analysis of peginterferon beta-1a compared with interferon beta-1a and glatiramer acetate in the treatment of relapsing-remitting multiple sclerosis in the United States.
SoCal Symposium on Glial-Neuronal Interactions in Health & Disease

Pages